Clinical Scorecard: Clinical Features and Prognostic Outcomes in Patients with Ocular Syphilis and HIV Co-Infection
At a Glance
Category
Detail
Condition
Ocular syphilis co-infected with HIV
Key Mechanisms
Syphilis causes diverse ocular manifestations including uveitis and optic retinitis affecting posterior eye segment; HIV co-infection impacts immune status influencing disease presentation and prognosis
Target Population
Patients diagnosed with both ocular syphilis and HIV infection, predominantly males under 40 years
Care Setting
Ophthalmology and HIV infection specialized clinical centers
Key Highlights
Ocular syphilis presents with multiple ocular manifestations: acute syphilitic posterior placoid chorioretinitis, confluent syphilitic retinochoroiditis, retinal vasculitis, and optic neuritis.
Visual acuity significantly improves after standard anti-syphilitic treatment with intravenous penicillin G followed by intramuscular benzathine penicillin G.
Majority of patients had posterior segment involvement with high prevalence of vitreous opacity (88.1%) and macular involvement (69.0%), with optic neuritis subgroup showing the worst baseline and final visual acuity.
Guideline-Based Recommendations
Diagnosis
Confirm HIV infection by CD4+ T lymphocyte count and HIV antibody testing (ELISA, chemiluminescence assay, Western blot confirmation).
Diagnose ocular syphilis by integrating ocular manifestations with laboratory tests including serum Treponema pallidum particle agglutination (TPPA) and rapid plasma reagin (RPR) for disease activity.
Exclude other infectious causes such as tuberculosis, cryptococcus, toxoplasmosis, and cytomegalovirus.
Management
Administer intravenous aqueous crystalline penicillin G (3–4 million units every 4 hours) for 10–14 days.
Follow with intramuscular benzathine penicillin G 2.4 million units weekly for three consecutive weeks.
Use local retrobulbar injection of methylprednisolone (20 mg) in cases of severe vitreous opacity.
Continue or initiate highly active antiretroviral therapy (HAART) for HIV management.
Monitoring & Follow-up
Assess best corrected visual acuity (BCVA) using decimal chart converted to logMAR at baseline and post-treatment.
Perform fundus photography and fluorescein fundus angiography to evaluate ocular manifestations and monitor vitreous opacity and macular involvement.
Monitor CD4+ T lymphocyte counts and HIV viral load to evaluate immune status.
Risks
Potential for temporary or permanent vision loss due to posterior segment involvement.
Worse visual prognosis in eyes with optic neuritis subtype.
Complicated diagnosis due to diverse ocular manifestations and co-existing infections.
Patient & Prescribing Data
31 patients (42 eyes) with ocular syphilis and HIV co-infection, mostly male (87.1%), median CD4+ count 132 cells/µl, majority on HAART.
Standard penicillin-based therapy significantly improved visual acuity; early diagnosis and treatment critical for better outcomes.
Clinical Best Practices
Integrate clinical ocular findings with specific serologic tests for accurate diagnosis of ocular syphilis in HIV patients.
Employ comprehensive ocular imaging and visual acuity assessments to classify ocular syphilis subtypes and guide prognosis.
Maintain HAART alongside syphilis treatment to optimize immune status and treatment response.
Consider adjunctive corticosteroid therapy for severe vitreous inflammation to improve visual outcomes.
Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.
